|
DCF -Bewertung von Alterity Therapeutics Limited (ATHE)
AU | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Alterity Therapeutics Limited (ATHE) Bundle
Unabhängig davon, ob Sie ein Investor oder ein Analyst sind, ist dieser (ATHE) DCF-Taschenrechner Ihre Anlaufstelle für eine genaue Bewertung. Ausgestattet mit realen Daten von Alterity Therapeutics Limited können Sie Prognosen anpassen und die Auswirkungen in Echtzeit beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 2.7 | 3.2 | 2.4 | 2.5 | 2.5 | 2.5 | 2.4 | 2.4 | 2.4 |
| Revenue Growth, % | 0 | 0 | 18.06 | -23.56 | 2.63 | -0.71712 | -0.71712 | -0.71712 | -0.71712 | -0.71712 |
| EBITDA | -8.3 | -12.0 | -10.8 | -10.9 | -12.2 | -1.5 | -1.5 | -1.5 | -1.5 | -1.4 |
| EBITDA, % | 100 | -446.13 | -339.46 | -447.2 | -486.94 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | .1 | .0 | .0 | .1 | .1 | .5 | .5 | .5 | .5 | .5 |
| Depreciation, % | 100 | 1.74 | 1.06 | 2.61 | 3.67 | 21.82 | 21.82 | 21.82 | 21.82 | 21.82 |
| EBIT | -8.4 | -12.1 | -10.8 | -11.0 | -12.3 | -1.5 | -1.5 | -1.5 | -1.5 | -1.4 |
| EBIT, % | 100 | -447.87 | -340.52 | -449.82 | -490.61 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 5.7 | 17.5 | 21.6 | 9.8 | 7.9 | 2.5 | 2.5 | 2.4 | 2.4 | 2.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 2.6 | 2.9 | 5.4 | 2.5 | 2.4 | 2.4 | 2.4 | 2.4 | 2.3 |
| Account Receivables, % | 100 | 95.09 | 91.14 | 220.84 | 100.56 | 97.24 | 97.24 | 97.24 | 97.24 | 97.24 |
| Inventories | .4 | .0 | .0 | .0 | .0 | .5 | .5 | .5 | .5 | .5 |
| Inventories, % | 100 | 0.000046087208 | 0 | 0 | 0 | 20 | 20 | 20 | 20 | 20 |
| Accounts Payable | .6 | .9 | 1.6 | 1.1 | .4 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
| Accounts Payable, % | 100 | 33.38 | 51.43 | 43.82 | 14.46 | 48.62 | 48.62 | 48.62 | 48.62 | 48.62 |
| Capital Expenditure | .0 | .0 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | -0.24131 | -1.74 | -0.18668 | -0.14236 | -0.46206 | -0.46206 | -0.46206 | -0.46206 | -0.46206 |
| Tax Rate, % | -0.24158 | -0.24158 | -0.24158 | -0.24158 | -0.24158 | -0.24158 | -0.24158 | -0.24158 | -0.24158 | -0.24158 |
| EBITAT | -8.1 | -12.1 | -10.9 | -11.0 | -12.3 | -1.5 | -1.5 | -1.5 | -1.4 | -1.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -7.8 | -13.9 | -10.5 | -14.0 | -10.0 | -.5 | -.9 | -.9 | -.9 | -.9 |
| WACC, % | 7.17 | 7.17 | 7.17 | 7.17 | 7.17 | 7.17 | 7.17 | 7.17 | 7.17 | 7.17 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -18 | |||||||||
| Present Terminal Value | -13 | |||||||||
| Enterprise Value | -16 | |||||||||
| Net Debt | -8 | |||||||||
| Equity Value | -8 | |||||||||
| Diluted Shares Outstanding, MM | 3,649 | |||||||||
| Equity Value Per Share | 0.00 |
What You Will Get
- Editable Forecast Inputs: Modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Alterity Therapeutics Limited’s (ATHE) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model tailored to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive Data: Alterity Therapeutics Limited's (ATHE) historical financial records and pre-populated projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Results: Observe the recalculation of Alterity's (ATHE) intrinsic value instantly.
- Visual Analytics: Interactive dashboard charts illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Alterity Therapeutics Limited's (ATHE) pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Evaluate the outputs and leverage the results for informed investment decisions.
Why Choose This Calculator for Alterity Therapeutics Limited (ATHE)?
- Precision: Utilizes actual financial data from Alterity Therapeutics for reliable results.
- Adaptability: Built for users to easily adjust and explore different input scenarios.
- Efficiency: Avoid the complexities of constructing a DCF model from the ground up.
- Expert-Level: Crafted with the expertise and attention to detail expected in high-level financial analysis.
- Intuitive: Simple to navigate, making it accessible for users without extensive financial modeling knowledge.
Who Should Use This Product?
- Healthcare Professionals: Understand the latest advancements in neurodegenerative disease treatments and apply them in practice.
- Researchers: Utilize data from clinical trials to enhance studies focused on therapeutic developments.
- Investors: Evaluate potential investment opportunities and assess the market position of Alterity Therapeutics Limited (ATHE).
- Pharmaceutical Analysts: Optimize your analysis with a comprehensive model tailored for biotech evaluations.
- Entrepreneurs: Learn from the strategies of established biotech firms like Alterity Therapeutics Limited (ATHE) to inform your own business plans.
What the Template Contains
- Pre-Filled DCF Model: Alterity Therapeutics Limited’s (ATHE) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital tailored for (ATHE).
- Financial Ratios: Assess Alterity’s (ATHE) profitability, leverage, and efficiency metrics.
- Editable Inputs: Modify assumptions such as growth rates, margins, and CAPEX to suit your analysis.
- Financial Statements: Access annual and quarterly reports to facilitate comprehensive evaluation.
- Interactive Dashboard: Effortlessly visualize key valuation metrics and outcomes for (ATHE).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.